Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II

Keyphrases

• Moderate to Severe 100%
• Patient-reported Outcomes 100%
• Impact on Patients 100%
• Bimekizumab 100%
• Hidradenitis Suppurativa 100%
• Placebo 41%
• HiSQOL 23%
• Dermatology Life Quality Index 17%
• Switcher 17%
• Health-related QOL 17%
• Symptom Questionnaire 17%
• Interleukin-17 (IL-17) 11%
• Disease Impact 11%
• Daily Diary 11%
• Change from Baseline 11%
• Clinically Meaningful Improvement 11%
• Severe Disease 5%
• Quality of Life 5%
• Quality of Life Questionnaire 5%
• Response Rate 5%
• Health-related Quality of Life 5%
• Itch 5%
• Index Score 5%
• Minimal Clinically Important Difference 5%
• Patient-reported Symptoms 5%
• Specific Patient 5%
• Very Severe 5%
• 4-point 5%
• Every 2 weeks 5%
• Score Reduction 5%
• IgG1 Monoclonal Antibody 5%
• Achievement Rate 5%

Medicine and Dentistry

• Hidradenitis Suppurativa 100%
• Bimekizumab 100%
• Patient-Reported Outcome 100%
• Placebo 41%
• Quality of Life 17%
• Dermatology Life Quality Index 17%
• Diseases 11%
• Pruritus 5%
• Monoclonal Antibody 5%
• Interleukin 17 5%
• Minimal Clinically Important Difference 5%
• Pain (Symptom) 5%
• Interleukin 17F 5%
• Immunoglobulin G1 5%

Immunology and Microbiology

• Hidradenitis Suppurativa 100%
• Bimekizumab 100%
• Monoclonal Antibody 5%
• Immunoglobulin G1 5%
• Interleukin 17F 5%
• Interleukin 17 5%